HK1066546A1 - Trifluoromethylpurines as phosphodiesterase 4 inhibitors - Google Patents
Trifluoromethylpurines as phosphodiesterase 4 inhibitorsInfo
- Publication number
- HK1066546A1 HK1066546A1 HK04109532.2A HK04109532A HK1066546A1 HK 1066546 A1 HK1066546 A1 HK 1066546A1 HK 04109532 A HK04109532 A HK 04109532A HK 1066546 A1 HK1066546 A1 HK 1066546A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- trifluoromethylpurines
- phosphodiesterase
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26719501P | 2001-02-08 | 2001-02-08 | |
US34482402P | 2002-01-07 | 2002-01-07 | |
PCT/US2002/022509 WO2002098878A1 (en) | 2001-02-08 | 2002-02-08 | Trifluoromethylpurines as phosphodiesterase 4 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1066546A1 true HK1066546A1 (en) | 2005-03-24 |
Family
ID=26952286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK04109532.2A HK1066546A1 (en) | 2001-02-08 | 2004-12-01 | Trifluoromethylpurines as phosphodiesterase 4 inhibitors |
Country Status (11)
Country | Link |
---|---|
US (4) | US7342021B2 (xx) |
EP (1) | EP1383767A1 (xx) |
JP (1) | JP4443215B2 (xx) |
KR (1) | KR100863622B1 (xx) |
CN (1) | CN100439370C (xx) |
AU (1) | AU2002313673B2 (xx) |
BR (1) | BR0207302A (xx) |
CA (1) | CA2438099A1 (xx) |
HK (1) | HK1066546A1 (xx) |
MX (1) | MXPA03007134A (xx) |
WO (1) | WO2002098878A1 (xx) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1130363C (zh) * | 1997-11-12 | 2003-12-10 | 三菱化学株式会社 | 嘌呤衍生物以及含有其作为有效成分的药物 |
BR0207302A (pt) * | 2001-02-08 | 2004-02-10 | Memory Pharm Corp | Trifluorometilpurinas como inibidores da fosfodiesterase 4 |
CA2494026A1 (en) * | 2002-08-08 | 2004-02-19 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
US7332486B2 (en) | 2002-08-08 | 2008-02-19 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
ES2295816T3 (es) | 2003-01-14 | 2008-04-16 | Arena Pharmaceuticals, Inc. | Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia. |
FR2851247B1 (fr) | 2003-02-19 | 2007-06-29 | Exonhit Therapeutics Sa | Methodes et compositions pour le traitement de pathologies degeneratives oculaires |
FR2856595B1 (fr) * | 2003-06-27 | 2008-05-30 | Exonhit Therapeutics Sa | Methodes et compositions pour le traitement de deficits cognitifs. |
EP2287165A3 (en) * | 2003-07-14 | 2011-06-22 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
MXPA06001758A (es) * | 2003-08-15 | 2006-08-11 | Irm Llc | Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk. |
CN100447143C (zh) * | 2003-08-15 | 2008-12-31 | Irm责任有限公司 | 作为rtk抑制剂的6-取代的苯胺基嘌呤 |
AU2004309420B2 (en) * | 2003-12-23 | 2008-10-30 | Novartis Ag | Bicyclic heterocyclic p-38 kinase inhibitors |
WO2005090352A1 (en) | 2004-03-16 | 2005-09-29 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor |
GB0416699D0 (en) | 2004-07-27 | 2004-09-01 | Prometic Biosciences Ltd | Prion protein ligands and methods of use |
JP5614930B2 (ja) | 2005-06-10 | 2014-10-29 | プロメティック バイオサイエンシズ,リミテッド | タンパク質結合性リガンドとしてのトリアジン |
SI1919896T1 (sl) | 2005-08-12 | 2010-04-30 | Suven Life Sciences Ltd | Aminoaril sulfonamidni derivati kot funkcionalni 5-HT6 ligandi |
US7923566B2 (en) | 2005-08-16 | 2011-04-12 | Suven Life Sciences Limited | Alternative process for the preparation of losartan |
PT2114878E (pt) | 2007-01-08 | 2011-03-10 | Suven Life Sciences Ltd | Compostos de 5-(heterociclil)-alquil-n-(arilsulfonil)indol e uso dos mesmos como ligandos de 5-ht6 |
EP2121633A2 (en) | 2007-02-12 | 2009-11-25 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
WO2008131501A2 (en) * | 2007-04-27 | 2008-11-06 | Katholieke Universiteit Leuven | New anti-viral nucleoside analogs |
BRPI0809873A2 (pt) | 2007-05-03 | 2018-11-13 | Suven Life Sciences Ltd | "composto, processo para a preparação do composto, método para o tratamento de uma desordem do sistema nervoso central, composição farmacêutica, uso do composto, método para testar antagonistas e antagonistas com seletividade para o receptor 5-th6 e método de tratamento" |
DK2200980T3 (da) | 2007-10-26 | 2011-11-21 | Suven Life Sciences Ltd | Aminoarylsulfonamidforbindelser og deres anvendelse som 5-HT6-ligander |
WO2009128057A2 (en) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Psycho-pharmaceuticals |
JP5536781B2 (ja) | 2008-09-17 | 2014-07-02 | スヴェン・ライフ・サイエンシズ・リミテッド | アリールスルホンアミドアミン化合物および5−ht6リガンドとしてのそれらの使用 |
US8318725B2 (en) | 2008-09-17 | 2012-11-27 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands |
KR20130137251A (ko) * | 2008-11-27 | 2013-12-16 | 고쿠리츠다이가쿠호우징 카가와다이가쿠 | 시클로부틸 푸린 유도체, 혈관신생 촉진제, 관강 형성 촉진제, 신경세포 성장 촉진제 및 의약품 |
BR112012016526A2 (pt) | 2010-01-05 | 2018-11-06 | Suven Life Sciences Ltd | composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de uma desordem do sistema nervoso central |
RU2569733C2 (ru) | 2010-02-12 | 2015-11-27 | Раквалиа Фарма Инк. | Агонисты 5-нт4-рецепторов для лечения деменции |
CN103539791B (zh) | 2010-09-22 | 2017-01-11 | 艾尼纳制药公司 | Gpr119 受体调节剂和对与其相关的障碍的治疗 |
WO2013130461A1 (en) | 2012-02-29 | 2013-09-06 | The Scripps Research Institute | Wee1 degradation inhibitors |
US8865723B2 (en) | 2012-10-25 | 2014-10-21 | Tetra Discovery Partners Llc | Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury |
US9663498B2 (en) | 2013-12-20 | 2017-05-30 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic compounds and their application in pharmaceuticals |
CN107405332A (zh) | 2015-01-06 | 2017-11-28 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病症的方法 |
US10301262B2 (en) | 2015-06-22 | 2019-05-28 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders |
EP3582772A1 (en) | 2017-02-16 | 2019-12-25 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
CN108395432A (zh) * | 2018-01-15 | 2018-08-14 | 吴江信凯医药科技有限公司 | 一种2-三氟甲基-6-氨基嘌呤的制备方法 |
US20210340122A1 (en) * | 2018-09-05 | 2021-11-04 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (sard) ligands and methods of use thereof |
RU2746012C2 (ru) * | 2019-05-13 | 2021-04-05 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ | Антидепрессантное средство для коррекции нежелательных побочных эффектов нейролептиков |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3917563A (en) | 1970-02-17 | 1975-11-04 | Japan Atomic Energy Res Inst | Process for the production of high molecular weight polyoxymethylene by the polymerization of tetraoxane |
US3919192A (en) * | 1972-05-22 | 1975-11-11 | Icn Pharmaceuticals | 5-Amino-4-substituted imidazole nucleotides |
US3917583A (en) * | 1972-08-04 | 1975-11-04 | Icn Pharmaceuticals | 2-Substituted cyclic AMP derivatives |
AR205247A1 (es) | 1973-02-07 | 1976-04-21 | Icn Pharmaceuticals | Procedimiento para preparar derivados de amp 2-substituidos |
JPS6210085A (ja) | 1985-07-05 | 1987-01-19 | Yoshitomi Pharmaceut Ind Ltd | トリフルオロメチルプリン誘導体 |
JPS62240622A (ja) | 1986-04-11 | 1987-10-21 | Asahi Glass Co Ltd | 抗腫瘍剤 |
GB8817651D0 (en) * | 1988-07-25 | 1988-09-01 | Smith Kline French Lab | Chemical compounds |
US5013829A (en) | 1989-04-26 | 1991-05-07 | University Of Iowa Research Foundation | Stable congener of 2',3'-dideoxyadenosine |
US5935978A (en) * | 1991-01-28 | 1999-08-10 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group |
JP3086912B2 (ja) | 1991-06-20 | 2000-09-11 | 工業技術院長 | フルオロアルキル基含有プリン誘導体及びその製造方法 |
DE69309030T2 (de) | 1992-06-15 | 1997-09-25 | Celltech Therapeutics Ltd | Trisubstituierte phenylderivate als selektive phosphodiesterase iv inhibitoren |
DE4230755A1 (de) | 1992-09-14 | 1994-03-17 | Schering Ag | Verwendung von PDE-Inhibitoren bei der Behandlung von Nieren- und Ureter-Erkrankungen |
US5814651A (en) * | 1992-12-02 | 1998-09-29 | Pfizer Inc. | Catechol diethers as selective PDEIV inhibitors |
TW263495B (xx) | 1992-12-23 | 1995-11-21 | Celltech Ltd | |
GB9312853D0 (en) * | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
US5525606A (en) * | 1994-08-01 | 1996-06-11 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines |
US5864037A (en) * | 1996-06-06 | 1999-01-26 | Euro-Celtique, S.A. | Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity |
JPH1072415A (ja) | 1996-06-26 | 1998-03-17 | Nikken Chem Co Ltd | 3−アニリノ−2−シクロアルケノン誘導体 |
US5744473A (en) * | 1996-09-16 | 1998-04-28 | Euro-Celtique, S.A. | PDE IV inhibitors: "bis-compounds" |
DE19702785A1 (de) | 1997-01-27 | 1998-07-30 | Bayer Ag | Neue cyclische Harnstoffderivate |
US6235736B1 (en) | 1997-06-24 | 2001-05-22 | Nikken Chemicals Co., Ltd. | 3-anilino-2-cycloalkenone derivatives |
CN1130363C (zh) | 1997-11-12 | 2003-12-10 | 三菱化学株式会社 | 嘌呤衍生物以及含有其作为有效成分的药物 |
BR9815170A (pt) | 1997-12-12 | 2000-10-10 | Euro Celtique S A Luxembourg | "método de obter composto aplicável no tratamento de asma em mamìferos" |
JP4160645B2 (ja) * | 1997-12-24 | 2008-10-01 | 大日本住友製薬株式会社 | 新規アデニン誘導体及びその医薬用途 |
JP3542482B2 (ja) | 1997-12-25 | 2004-07-14 | 日研化学株式会社 | 3−アニリノ−2−シクロアルケノン誘導体 |
JPH11264847A (ja) | 1998-03-18 | 1999-09-28 | Advantest Corp | スペクトラム・アナライザ |
JP2000072773A (ja) * | 1998-08-28 | 2000-03-07 | Zeria Pharmaceut Co Ltd | プリン誘導体 |
US6319928B1 (en) * | 1998-11-30 | 2001-11-20 | Euro-Celtique, S.A. | Purine derivatives having phosphodiesterase IV inhibition activity |
DE19935209A1 (de) | 1999-07-27 | 2001-02-08 | Truss Michael C | Verwendung von Substanzen, die den intrazellulären Gehalt von zyklischem Adenosinmonophosphat (cAMP) erhöhen oder die Aktivität cAMP-bindender Proteine stimulieren, zur Behandlung von Erkrankungen der Harnblase |
GB0011802D0 (en) | 2000-05-16 | 2000-07-05 | Smithkline Beecham | Method for enhancing cognitive function |
BR0207302A (pt) | 2001-02-08 | 2004-02-10 | Memory Pharm Corp | Trifluorometilpurinas como inibidores da fosfodiesterase 4 |
US7332486B2 (en) * | 2002-08-08 | 2008-02-19 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
CA2494026A1 (en) * | 2002-08-08 | 2004-02-19 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
US7371737B2 (en) * | 2004-09-09 | 2008-05-13 | Solvay Pharmaceuticals, B.V. | 2-substituted-6-trifluoromethyl purine derivatives with adenosine-A3 antagonistic activity |
-
2002
- 2002-02-08 BR BR0207302-1A patent/BR0207302A/pt not_active IP Right Cessation
- 2002-02-08 CA CA002438099A patent/CA2438099A1/en not_active Abandoned
- 2002-02-08 EP EP02753379A patent/EP1383767A1/en not_active Withdrawn
- 2002-02-08 KR KR1020037010420A patent/KR100863622B1/ko not_active IP Right Cessation
- 2002-02-08 AU AU2002313673A patent/AU2002313673B2/en not_active Ceased
- 2002-02-08 US US10/067,996 patent/US7342021B2/en not_active Expired - Fee Related
- 2002-02-08 CN CNB02807890XA patent/CN100439370C/zh not_active Expired - Fee Related
- 2002-02-08 JP JP2003501999A patent/JP4443215B2/ja not_active Expired - Fee Related
- 2002-02-08 MX MXPA03007134A patent/MXPA03007134A/es active IP Right Grant
- 2002-02-08 WO PCT/US2002/022509 patent/WO2002098878A1/en active IP Right Grant
-
2004
- 2004-05-14 US US10/845,354 patent/US20040242598A1/en not_active Abandoned
- 2004-12-01 HK HK04109532.2A patent/HK1066546A1/xx not_active IP Right Cessation
-
2007
- 2007-12-14 US US11/956,871 patent/US20080119495A1/en not_active Abandoned
-
2009
- 2009-09-22 US US12/564,636 patent/US20100010020A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20040008127A (ko) | 2004-01-28 |
KR100863622B1 (ko) | 2008-10-15 |
EP1383767A1 (en) | 2004-01-28 |
US20040242598A1 (en) | 2004-12-02 |
CN1501927A (zh) | 2004-06-02 |
CA2438099A1 (en) | 2002-12-12 |
JP2004528391A (ja) | 2004-09-16 |
US7342021B2 (en) | 2008-03-11 |
AU2002313673B2 (en) | 2006-09-07 |
MXPA03007134A (es) | 2004-10-15 |
US20030045533A1 (en) | 2003-03-06 |
CN100439370C (zh) | 2008-12-03 |
JP4443215B2 (ja) | 2010-03-31 |
US20080119495A1 (en) | 2008-05-22 |
US20100010020A1 (en) | 2010-01-14 |
WO2002098878A1 (en) | 2002-12-12 |
BR0207302A (pt) | 2004-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1066546A1 (en) | Trifluoromethylpurines as phosphodiesterase 4 inhibitors | |
PL373301A1 (en) | Phosphodiesterase 4 inhibitors | |
HK1064668A1 (en) | Polycyclic guanine phosphodiesterase v inhibitors | |
PL369728A1 (en) | Pyrrolopyrimidines as phosphodiesterase vii inhibitors | |
HK1080073A1 (en) | Alkyne-aryl phosphodiesterase-4 inhibitors | |
SI1671949T1 (sl) | Substituirani pridinilamini | |
TW595857U (en) | 091219345 | |
IL152872A0 (en) | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | |
PL363391A1 (en) | Phthalayinone-piperidino-derivatives as pde4 inhibitors | |
PL367308A1 (en) | Novel use | |
PL362643A1 (en) | Substituted fluoroalcoxyphenylsulfonylurea | |
GB0115181D0 (en) | Novel use | |
GB0100762D0 (en) | Novel use | |
PL368050A1 (en) | Substituted 4-aminocyclohexanols | |
EP1364653A4 (en) | CASOASE-3 INHIBITORS | |
GB0202187D0 (en) | "Inhibitors" | |
PL364601A1 (en) | Substituted benzo-nitro-heterocycles | |
ZA200306119B (en) | Trifluoromethylpurines as phosphodiesterase 4 inhibitors. | |
GB0128453D0 (en) | Inhibitors | |
GB0101135D0 (en) | Inhibitors | |
GB0101134D0 (en) | Inhibitors | |
AU2002317788A1 (en) | Imidazotriazines for use as phosphodiesterase inhibitors | |
SI1296981T1 (en) | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | |
AU2002233669A1 (en) | Casoase 3 inhibitors | |
GB0127860D0 (en) | Surfaces |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20130208 |